Table 3.

Independent effects of CCL3L1-CCR5 GRGs on CD4⁺ recovery

Pre-HAART CD4			Low GRG	Moderate-high GRG	P
Model 1: unadjusted
	During first 2 years of HAART
		≥ 350	7.07 (1.00)a	6.87 (1.44)	0.9093
		< 350	6.05 (0.76)	5.13 (0.89)	0.4332
	After 2 years of HAART
		≥ 350	0.65 (0.40)	−0.65 (0.62)	0.0808
		< 350	1.90 (0.35)	0.12 (0.34)	0.0004
Model 2: adjusted for covariatesb
	During first 2 years of HAART
		≥ 350	5.16 (1.19)	4.58 (1.49)	0.7611
		< 350	6.03 (0.69)	4.49 (0.62)	0.1008
	After 2 years of HAART
		≥ 350	1.01 (0.50)	−0.45 (0.59)	0.0626
		< 350	2.07 (0.40)	0.11 (0.38)	0.0007
Model 3: adjusted for covariatesb and HLA-A*68, HLA-B*57 and HLA-C*16 alleles
	During first 2 years of HAART
		≥ 350	4.77 (1.21)	5.15 (1.71)	0.8565
		< 350	6.36 (0.76)	4.97 (0.33)	0.0971
	After 2 years of HAART
		≥ 350	1.02 (0.48)	−1.55 (0.68)	0.0028
		< 350	2.44 (0.46)	0.20 (0.36)	0.0003
Model 4; adjusted for covariatesb and HLA allele frequency score
	During first 2 years of HAART
		≥ 350	4.72 (0.17)	5.15 (1.57)	0.8258
		< 350	6.38 (0.78)	4.97 (0.43)	0.1206
	After 2 years of HAART
		≥ 350	1.01 (0.49)	−1.56 (0.90)	0.0033
		< 350	2.45 (0.46)	0.19 (0.36)	0.0003

Data are for subjects from the WHMC HIV⁺ cohort and indicate the mean (s.e.m.) rate of change of CD4⁺ cell counts per month after initiation of HAART, as estimated by regression coefficients computed by linear GEE.

^aValues are defined as in Table 1.

^bCovariates were calendar year of HAART initiation, age at HAART initiation, pre-HAART viral load, achievement of viral load suppression and prior receipt of antiretroviral therapy. Pre-HAART CD4⁺ T cell count is as defined in Table 2. Similar results for models 1 and 2 were obtained in subjects who were naive for HAART (Supplementary Table 2 online).